R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Veronica R. Smith,Uday R. Popat,Stefan O. Ciurea,Yago Nieto,Paolo Anderlini,Gabriela Rondon,Amin M. Alousi,Muzaffar H. Qazilbash,Partow Kebriaei,Issa F. Khouri,Marcos de Lima,Richard E. Champlin,Chitra Hosing +12 more
TL;DR: Patients with multiple myeloma and all but one patient with lymphoma collected the minimum required number of CD34+ cells to proceed with autologous stem cell transplantation, and plerixafor was well tolerated; no grade 2 or higher non‐hematologic toxic effects were observed.
Journal ArticleDOI
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Uday R. Popat,Rohtesh S. Mehta,Roland L. Bassett,Julianne Chen,Benigno C. Valdez,Jitesh D. Kawedia,Sairah Ahmed,Amin M. Alousi,Paolo Anderlini,Geath Al-Atrash,Qaiser Bashir,Stefan O. Ciurea,Chitra Hosing,Jin S. Im,Roy B. Jones,Partow Kebriaei,Issa F. Khouri,David Marin,Yago Nieto,Amanda Olson,Betul Oran,Simrit Parmar,Katayoun Rezvani,Muzaffar H. Qazilbash,Nina Shah,Samer A. Srour,Elizabeth J. Shpall,Richard E. Champlin,Borje S. Andersson +28 more
TL;DR: Myeloablative doses of busulfan administered in a timed-sequential manner with fludarabine is associated with low non-relapse mortality in older patients and patients with comorbidities.
Journal ArticleDOI
Long-term outcomes of Sleeping Beauty–generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas
Samer A. Srour,Harjeet Singh,Jessica McCarty,E. de Groot,Helen Huls,Gabriella Rondon,M.H. Qazilbash,Stefan O. Ciurea,G. Bardelli,J. Buck,Amin M. Alousi,Y. Nieto,Katy Rezvani,David Marin,U. Popat,Chitra Hosing,Elizabeth J. Shpall,William G. Wierda,Hagop M. Kantarjian,Richard E. Champlin,Laurence J.N. Cooper,Partow Kebriaei +21 more
Journal ArticleDOI
Ocular graft vs. host disease experience from MD Anderson Cancer Center: Newly described clinical spectrum and new approach to the management of stage III and IV ocular GVHD
Journal ArticleDOI
A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy
Minying Zhang,Sourindra Maiti,Chantale Bernatchez,Helen Huls,Brian Rabinovich,Richard E. Champlin,Luis M Vence,Patrick Hwu,Laszlo Radvanyi,Laszlo Radvanyi,Laurence J.N. Cooper,Laurence J.N. Cooper +11 more
TL;DR: DTEA can rapidly and sensitively track changes in TCRVα and Vβ gene usages in T-cell pools following immune interventions, such as adoptive T- cell transfer, and may also be used to assess impact of vaccination or reconstitution of T-cells compartment after hematopoietic stem cell transplantation.